Aducanumab is the first new dementia drug treatment to come to market since 2003.
Featured news and events
The report launch of From Plan to Impact IV: Progress towards targets of the WHO Global action plan on dementia will take place virtually on 26 May.
ADI 2020 will take place from Thursday, 10 December until Saturday, 12 December and feature over 1,500 delegates from around the world.
We have a new website, with updated design and content. The site works better on mobile devices and brings together our resources, member information and programmes so they are easy to find.
A new policy briefing, co-authored by ADI, thoroughly examines dementia care policy in Qatar.
A new data platform AD Workbench was launched by the Alzheimer’s Disease Data Initiative (ADDI).
Promising results from a clinical trial have been published in the peer-reviewed journal of the Alzheimer’s Association.
The US Food and Drug Administration has reviewed clinical trial data for Biogen’s drug aducanumab, which aims to treat cognitive and functional decline in Alzheimer’s disease.
‘Dementia Innovation Readiness Index 2020: 30 Global Cities’ calls strongly for cities to fulfil their commitments under the WHO’s Global action plan on dementia to engage fully with their national dementia plans.
Alzheimer’s Disease International (ADI) launches the world’s most comprehensive report on dementia-related design and the built environment.